The first experience of using of {99}mTc-Al[2]O[3] for detection of sentinel lymph nodes in breast cancer; IOP Conference Series: Materials Science and Engineering; Vol. 135 : Issues of Physics and Technology in Science, Industry and Medicine

Xehetasun bibliografikoak
Parent link:	IOP Conference Series: Materials Science and Engineering Vol. 135 : Issues of Physics and Technology in Science, Industry and Medicine.— 2016.— [012011, 5 p.]
Erakunde egilea:	Национальный исследовательский Томский политехнический университет (ТПУ) Физико-технический институт (ФТИ) Лаборатория № 31 ядерного реактора (Лаборатория № 31 ЯР)
Beste egile batzuk:	Doroshenko A., Chernov V. I. Vladimir Ivanovich, Medvedeva А. А. Anna Aleksndrovna, Zelchan R. V. Roman Vladimirovich, Slonimskaya E., Varlamova N. V. Natalya Valeryevna, Skuridin V. S. Viktor Sergeyevich, Dergilev A., Sinilkin I. G. Ivan Gennadjevich
Gaia:	Title screen Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. Materials and methods. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n=34) were injected with radioactive {99m}Tc-Al[2]0[3], and Group II patients (n=30) received {99m}Tc-labeled phytate colloid. Results. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. At 18 hours after {99m}Tc-Al[2]0[3] injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II patients, SLNs were detected in 27 patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. Conclusion. The new radiopharmaceutical based on the {99m}Tc -Al[2]0[3] demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. Sensitivity and specificity of {99m}Tc -Al[2]0[3] were 100% for both SPECT and intraoperative gamma probe identification.
Hizkuntza:	ingelesa
Argitaratua:	2016
Gaiak:	электронный ресурс труды учёных ТПУ лимфатические узлы рак радиофармпрепараты компьютерная томография радиоактивные изотопы
Sarrera elektronikoa:	http://dx.doi.org/10.1088/1757-899X/135/1/012011 http://earchive.tpu.ru/handle/11683/34799
Formatua:	Baliabide elektronikoa Liburu kapitulua
KOHA link:	https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=650264